Notice of Consultation on the Prescription Drug List (PDL): Epinephrine chloride (topical solution)

From Health Canada

Current status: Open

Opened on August 12, 2019 and will close to new input on October 26, 2019.

This Consultation provides an opportunity to comment on the proposal to add epinephrine solution for hemostasis when applied to the mucosa at a concentration equal to or greater than 1 mg/ ml (1:1000) to the Prescription Drug List (PDL).

Join in: how to participate

Send us an email: Send an email to hc.drug.prescription.status-statut.dordonnance.des.drogues.sc@canada.ca with your ideas or comments to make yourself heard.

Participate by mail: Send a letter with your ideas and input to the address in contact information below.

Who is the focus of this consultation

We will engage with:

Goals of the consultation

Products containing “Epinephrine solution for hemostasis when applied to the mucosa at a concentration equal to or greater than 1 mg/ ml (1:1000)” will be considered prescription products under the Food and Drugs Regulations (FDR), and as such, would no longer be considered NHPs.

Contact us

Health Canada

Prescription Drug Status Committee

Address Locator 3102C3

Holland Cross, Tower B

1600 Scott Street

Ottawa, Ontario

K1A 0K9

 

Email: hc.drug.prescription.status-statut.dordonnance.des.drogues.sc@canada.ca

Telephone: 343-998-9304

Facsimile: 613-941-1812

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: